Deuruxolitinib significantly improves hair satisfaction in AA

In a post-hoc analysis of the THRIVE-AA1 and THRIVE-AA2 trials, the JAK1/JAK2 inhibitor deuruxolitinib significantly boosted hair satisfaction in participants who responded to treatment, with effects emerging as soon as week 12. Thus, treatment not only stimulated hair growth but also added to the well-being of patients with alopecia areata (AA).

AA is associated with anxiety and depression, as well as declines in social functioning and productivity, thus reducing the quality-of-life of many patients [1,2]. The double-blind, placebo-controlled phase 3 THRIVE-AA1 (NCT04518995) and THRIVE-AA2 (NCT04797650) trials evaluated the efficacy of deuruxolitinib in patients with severe AA (≥50% scalp hair loss measured by the Severity of Alopecia Tool, SALT) [3]. The trials’ primary endpoint, a SALT score ≤20 at week 24, was achieved by 31% of participants in the deuruxolitinib 8 mg twice daily group, compared with 0.8% in the placebo group.

Dr Paradi Mirmirani (Kaiser Permanente Vallejo Medical Center, CA, USA) presented a post-hoc pooled analysis, which examined the change in patient-reported hair satisfaction over 24 weeks in adult participants with AA who responded to deuruxolitinib 8 mg twice daily in the THRIVE-AA1 and THRIVE-AA2 trials [4]. Most participants had very significant hair loss. In both studies, 31.0% of participants randomised to deuruxolitinib achieved a SALT score ≤20 at week 24 and were included in the current analysis. The shift in hair satisfaction among responders to deuruxolitinib was assessed in the 5-point Hair Satisfaction Patient Reported Outcome (SPRO) scale.

By week 24, 95.7% of participants treated with deuruxolitinib who were initially dissatisfied with their hair reported satisfaction (P<0.0001; see Figure). This shift occurred progressively. “As early as week 12, we saw impressive results: 79% of participants flipped from very dissatisfied to satisfied or very satisfied,” said Dr Mirmirani. No participants in the placebo group achieved similar outcomes.

Figure: Almost 80% of participants were very satisfied or satisfied with the hair on their scalp at week 12, which further increased to 95.7% at week 24 [1]

SALT, Severity of Alopecia Tool; SPRO, responders defined as patients who were “satisfied” or “very satisfied” in the Satisfaction of Hair Patient Reported Outcome Questionnaire.

These findings underscore the efficacy of deuruxolitinib in not only promoting hair regrowth but also improving patients’ overall satisfaction with their appearance.

1. 
   
   1. Mesinkovska N, et al. J Investig Dermatol Symp Proc 2020;20:S62-8.
   2. Muntyanu A, et al. J Eur Acad Dermatol Venereol 2023; Jan 27. DOI: 10.1111/jdv.18926.
   3. King B, et al. J Am Acad Dermatol 2024;37(8):1490-1520.
   4. Mirmirani P. Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials. FC04.04, EADV Congress 2024, 25–28 September, Amsterdam, the Netherlands.

Copyright ©2024 Medicom Medical Publishers



Posted on 6 November 20246 November 2024